TeleHepC Treatment Trial

Hepatitis C Clinical Trial

Official title:

Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study: Tele-HCV Treatment Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04798521
• Other study ID #: TeleHepC
• Secondary ID: UH3DA044831
• Status: Completed
• Phase: N/A
• Start date: June 30, 2020
• Est. completion date: January 10, 2024

Study information

• Verified date: March 2024
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main goal of this study is to test the efficacy of a peer-facilitated telemedicine HCV treatment implementation strategy for people who use drugs versus local HCV treatment referral for achieving HCV sustained viral response at 12 weeks post-treatment (SVR12).

Description:

Non-blinded, randomized controlled trial. In-depth qualitative interviews assess attitudes and barriers to treatment.

In Phase 1, potential participants will be pulled from a convenience sample at a Portland clinic providing care for the urban area. An initial target sample of 100 Hepatitis C positive participants will be enrolled for DBS validation. Power will be reassessed based on feedback from receiver operating curve model and additional participants enrolled up to a total of 100 Hepatitis C Positive participants, if necessary. A total of 500 potential participants can be screened expecting 1 in every 4 participants will be positive HCV.

In Phase 2, rural peer care coordinators (PCCs) and research assistants recruit up to 200 PWUD participants from high-needs rural Oregon counties. Study staff specifically target untreated populations recruited from local syringe exchange programs and direct community outreach (e.g. community barbeques, parks, homeless shelters, food pantries, etc.). Participants are encouraged to refer others for study screening.

A subset of up to 40 study participants will complete in-depth qualitative interviews regarding their experiences of hepatitis C treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 203
• Est. completion date: January 10, 2024
• Est. primary completion date: August 25, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. live in the study area

2. have injected drugs or report recreational opioid use without injection in the last 90 days

3. are age 18 or greater

4. have chronic active, untreated hepatitis C (defined as positive HCV RNA)

5. are seeking treatment for hepatitis C infection.

6. are able to communicate in English (this is due to the fact that less than 5% of the population in which we are targeting will be non-English speaking; see "Non-English Speaking Subjects" for additional information).

7. are enrolled in health insurance

Exclusion Criteria:

1. Have decompensated cirrhosis, defined as Child-Turcotte-Pugh (CTP) score of 7 or greater, or CTP B cirrhosis. CTP scoring is a composite of laboratory metrics (bilirubin, albumin, PT/INR) and clinical findings, including:

1. increased abdominal or lower extremity swelling

2. confusion consistent with hepatic encephalopathy

2. Are pregnant or breastfeeding

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis C

Intervention

Other:
• Tele-HCV
Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
• Community Linkage to Care
Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.

Locations

Country	Name	City	State
United States	Central City Concern	Portland	Oregon
United States	Comagine Health	Portland	Oregon
United States	HIV Alliance	Roseburg	Oregon

Sponsors (4)

Lead Sponsor	Collaborator
Oregon Health and Science University	Comagine Health, HIV Alliance, Oregon Health Authority

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Viral Response	Sustained viral response post treatment. The viral response will be measured via a blood test.	12 weeks post treatment
Secondary	Treatment Initiation	HCV treatment initiation	4 weeks
Secondary	Treatment Completion	HCV treatment completion, filled final prescription. 90% of HCV pills taken	36 weeks post treatment
Secondary	Engagement in harm reduction resources	Participants complete surveys to assess whether or not they are regularly engaging in substance use and harm reduction resources in the community.	Throughout study completion, up to 36 weeks